JP2018148890A5 - - Google Patents

Download PDF

Info

Publication number
JP2018148890A5
JP2018148890A5 JP2018076758A JP2018076758A JP2018148890A5 JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5 JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5
Authority
JP
Japan
Prior art keywords
vector
polypeptide
seq
protein
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018076758A
Other languages
English (en)
Japanese (ja)
Other versions
JP6606571B2 (ja
JP2018148890A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018148890A publication Critical patent/JP2018148890A/ja
Publication of JP2018148890A5 publication Critical patent/JP2018148890A5/ja
Application granted granted Critical
Publication of JP6606571B2 publication Critical patent/JP6606571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018076758A 2014-11-04 2018-04-12 治療用hpv16ワクチン Active JP6606571B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04
EP14191660.1 2014-11-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017523902A Division JP6325751B2 (ja) 2014-11-04 2015-11-03 治療用hpv16ワクチン

Publications (3)

Publication Number Publication Date
JP2018148890A JP2018148890A (ja) 2018-09-27
JP2018148890A5 true JP2018148890A5 (https=) 2018-12-13
JP6606571B2 JP6606571B2 (ja) 2019-11-13

Family

ID=52020908

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523902A Active JP6325751B2 (ja) 2014-11-04 2015-11-03 治療用hpv16ワクチン
JP2018076758A Active JP6606571B2 (ja) 2014-11-04 2018-04-12 治療用hpv16ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017523902A Active JP6325751B2 (ja) 2014-11-04 2015-11-03 治療用hpv16ワクチン

Country Status (34)

Country Link
US (4) US9701721B2 (https=)
EP (2) EP3215187B1 (https=)
JP (2) JP6325751B2 (https=)
KR (1) KR20170083562A (https=)
CN (1) CN107075521B (https=)
AR (1) AR102527A1 (https=)
AU (2) AU2015341926B2 (https=)
BR (1) BR112017009177A2 (https=)
CA (1) CA2965562C (https=)
CL (1) CL2017001089A1 (https=)
CO (1) CO2017004838A2 (https=)
CY (1) CY1121377T1 (https=)
DK (1) DK3215187T3 (https=)
EA (1) EA035461B1 (https=)
ES (1) ES2697903T3 (https=)
HR (1) HRP20181895T1 (https=)
HU (1) HUE040440T2 (https=)
IL (1) IL251895B (https=)
LT (1) LT3215187T (https=)
MA (2) MA46378A (https=)
MD (1) MD3215187T2 (https=)
MX (1) MX379069B (https=)
MY (1) MY181175A (https=)
NZ (1) NZ730802A (https=)
PL (1) PL3215187T3 (https=)
PT (1) PT3215187T (https=)
RS (1) RS58080B1 (https=)
SA (1) SA517381457B1 (https=)
SG (1) SG11201702997YA (https=)
SI (1) SI3215187T1 (https=)
SM (1) SMT201800602T1 (https=)
TW (2) TWI694147B (https=)
WO (1) WO2016071306A1 (https=)
ZA (1) ZA201703055B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
KR20180042295A (ko) 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
TW201923084A (zh) * 2017-09-23 2019-06-16 德商百靈佳殷格翰維美迪加股份有限公司 副黏液病毒科(paramyxoviridae)表現系統
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
US12599656B2 (en) * 2018-03-12 2026-04-14 Stemcell Technologies Canada Inc. Methods for treating HPV-associated diseases
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Hpvポリペプチドおよびil-2をコードするポックスウイルスと抗pd-l1抗体の組合せ
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4149530A1 (en) * 2020-05-12 2023-03-22 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
KR20230125200A (ko) * 2020-11-24 2023-08-29 마 무초우 조 인간 유두종 바이러스에 대한 dna 백신 및 이를 사용하는 방법
JP2024539188A (ja) * 2021-10-22 2024-10-28 イノビオ ファーマシューティカルズ,インコーポレイティド 肛門高悪性度扁平上皮内病変(hsil)を治療するための組成物及び方法
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
EP1809750B1 (en) 2004-11-08 2012-03-21 ChromaGenics B.V. Selection of host cells expressing protein at high levels
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2008092854A2 (en) * 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP3188752A2 (en) 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
KR20180042295A (ko) * 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신
EP3452087A1 (en) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations

Similar Documents

Publication Publication Date Title
JP2018148890A5 (https=)
JP2019068852A5 (https=)
JP2015533841A5 (https=)
CA2741724C (en) Promoters for recombinant viral expression
CN104755622B (zh) 用于稳健t细胞和抗体应答的pr13.5启动子
RU2462513C2 (ru) Векторы для множественной генной экспрессии
JP2016510989A5 (https=)
US12064477B2 (en) HPV vaccine
JP2014207903A5 (https=)
CN101426810A (zh) 基于hpv-18的乳头瘤病毒疫苗
JP2010516287A5 (https=)
JP2016539946A5 (https=)
KR20090005011A (ko) Hpv-16-기재의 유두종바이러스 백신
JP2017507918A (ja) Hpvおよび関連する疾病のための免疫増強治療ワクチン
RU2013102035A (ru) Полипептиды е2 папилломавируса, применяемые для вакцинации
JP2019514943A5 (https=)
JP2016074727A5 (https=)
KR20180084139A (ko) 11형 인유두종 바이러스 엘1 단백질의 돌연변이체
US20230233670A1 (en) A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
JP2021528367A5 (https=)
US10894966B2 (en) Virus-based expression vectors and uses thereof
JP7224332B2 (ja) ヒトパピローマウイルス16型のl1タンパク質の変異体
JP2019528271A5 (https=)
JP2015524420A5 (https=)
AU2017236578B2 (en) HCV vaccines